Inventi Rapid: Cardiology & Haematology

Inventi:hch/33689/21

Role of Iron Chelation Therapy in Beta Thalassaemia

Beta thalassemia is an autosomal recessive inherited disease caused by mutations in a gene. Most of the beta-thalassemia patients underwent multiple blood transfusions it leads to accumulation of iron in the body and other complications like Splenomegaly can be seen. To decreases the Serum ferritin levels, complications, increases the time duration of blood transfusion Iron chelator’s like deferasirox are used. And Folic supplements, vitamin supplements are given to improve quality of life. Patient education about disease is important and Vaccination is needed for these patients. It is a retrospective, observational study was conducted in a tertiary care hospital in Telangana region. The data were collected from case structured questionnaire after taking informed consent from the patients. In our Study 65 patients were taken in that most of them are homozygous type of DNA and belong to rural area. In our study 78.46% patients underwent blood transfusion monthly once followed by 12.30% patients monthly twice and 7.69% patients transfused monthly once/ twice and 1.53% patients transfused 2-3 months. Our study is based on iron chelation therapy 86.15% of the patients are treated with deferasirox followed by 6.15% patients treated with Kelfer and 7.69% patients were not started the chelator’s during our study. With deferasirox most of the patients shows the positive response therefore decrease in Serum ferritin levels is 75.38%, some patients showing alteration in Serum ferritin levels is 16.92%,only few patients are without any chelator is 7.69%....